Clinical and Bioanalytical Insights in the Research and Development of Respiratory drugs
This webinar will provide an R&D update in the respiratory area and cover the need to increase the performance of clinical trials by using new biomarkers and efficient study designs, based on modeling and simulation exercises and new site management models.
sponsored by SGS
Webinar Description:
Substantial success has been realized in the treatment of common respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory allergies. By acquiring a deeper understanding of inflammatory mechanisms, new targets for treating these diseases are becoming available. Consequently, researchers are poised to unlock potential advances in research for unmet medical needs for often lifethreatening respiratory disorders such as cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), and an infectious diseases such as Respiratory Syncytial Virus (RSV).
This webinar provides an R&D update in the respiratory area and covers the need to increase the performance of clinical trials by using new biomarkers and efficient study designs, based on modeling and simulation exercises and new site management models.
Speaker 1: Nicolas Fourrier, SGS – Director Biomarker and Biopharmaceutical Testing
Speaker 2: Robert Lins, SGS - Senior Clinical Adviser
